Q3 Earnings Estimate for Ardelyx Issued By Leerink Partnrs

Ardelyx, Inc. (NASDAQ:ARDX) – Investment analysts at Leerink Partnrs issued their Q3 2025 earnings estimates for Ardelyx in a research note issued to investors on Thursday, February 20th. Leerink Partnrs analyst R. Ruiz expects that the biopharmaceutical company will post earnings of ($0.03) per share for the quarter. The consensus estimate for Ardelyx’s current full-year earnings is ($0.18) per share. Leerink Partnrs also issued estimates for Ardelyx’s Q4 2025 earnings at ($0.01) EPS, FY2026 earnings at $0.40 EPS and FY2027 earnings at $1.00 EPS.

Ardelyx (NASDAQ:ARDX) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.02 EPS for the quarter, meeting analysts’ consensus estimates of $0.02. The business had revenue of $116.13 million during the quarter, compared to the consensus estimate of $111.16 million. Ardelyx had a negative return on equity of 25.74% and a negative net margin of 11.73%.

ARDX has been the subject of a number of other research reports. Raymond James reissued a “strong-buy” rating and set a $13.00 target price (down previously from $15.00) on shares of Ardelyx in a research report on Friday. HC Wainwright reaffirmed a “neutral” rating and set a $5.50 price objective on shares of Ardelyx in a report on Friday. Citigroup cut their price target on shares of Ardelyx from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Piper Sandler upped their price objective on shares of Ardelyx from $7.00 to $8.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Finally, Jefferies Financial Group dropped their price objective on shares of Ardelyx from $11.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, January 2nd. Three research analysts have rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Ardelyx currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.93.

Ardelyx Stock Down 11.6 %

Shares of NASDAQ ARDX opened at $5.06 on Monday. The company has a 50 day simple moving average of $5.30 and a 200 day simple moving average of $5.63. The firm has a market cap of $1.20 billion, a PE ratio of -31.59 and a beta of 0.85. Ardelyx has a 1 year low of $4.32 and a 1 year high of $9.83. The company has a debt-to-equity ratio of 0.64, a current ratio of 4.03 and a quick ratio of 3.87.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ARDX. Ensign Peak Advisors Inc boosted its holdings in shares of Ardelyx by 3.1% during the 4th quarter. Ensign Peak Advisors Inc now owns 73,950 shares of the biopharmaceutical company’s stock worth $375,000 after purchasing an additional 2,200 shares during the last quarter. B. Riley Wealth Advisors Inc. lifted its stake in Ardelyx by 3.4% in the third quarter. B. Riley Wealth Advisors Inc. now owns 90,000 shares of the biopharmaceutical company’s stock worth $599,000 after acquiring an additional 3,000 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Ardelyx by 2.3% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 154,625 shares of the biopharmaceutical company’s stock worth $788,000 after acquiring an additional 3,550 shares in the last quarter. Swiss National Bank grew its holdings in Ardelyx by 1.0% during the 4th quarter. Swiss National Bank now owns 463,100 shares of the biopharmaceutical company’s stock worth $2,348,000 after acquiring an additional 4,800 shares in the last quarter. Finally, Orion Portfolio Solutions LLC boosted its holdings in shares of Ardelyx by 42.7% in the 4th quarter. Orion Portfolio Solutions LLC now owns 16,486 shares of the biopharmaceutical company’s stock valued at $84,000 after buying an additional 4,933 shares in the last quarter. Hedge funds and other institutional investors own 58.92% of the company’s stock.

Insider Activity

In other news, insider Laura A. Williams sold 4,941 shares of the business’s stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $5.62, for a total transaction of $27,768.42. Following the transaction, the insider now owns 303,804 shares of the company’s stock, valued at approximately $1,707,378.48. The trade was a 1.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director David M. Mott bought 213,300 shares of the business’s stock in a transaction dated Thursday, December 19th. The shares were bought at an average cost of $4.67 per share, for a total transaction of $996,111.00. Following the transaction, the director now owns 1,638,765 shares in the company, valued at approximately $7,653,032.55. The trade was a 14.96 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 141,408 shares of company stock valued at $761,963 in the last ninety days. Corporate insiders own 5.90% of the company’s stock.

About Ardelyx

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.